ロード中...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Russo |
| 出版事項: |
ABV-press
2021-09-01
|
| シリーズ: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| 主題: | |
| オンライン･アクセス: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|